Prognostic significance of RUNX3 expression in human melanoma

Cancer

Volumn 117, Issue 12, 2011, Pages 2719-2727

  Zhang, Zhizhong ^a   Chen, Guangdi ^a   Cheng, Yabin ^a   Martinka, Magdalena ^b   Li, Gang ^a,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

^c JACK BELL RESEARCH CENTRE   (Canada)

Author keywords

melanoma; prognosis; RUNX3; tissue microarray

Indexed keywords

TRANSCRIPTION FACTOR RUNX3;

ADULT; AGED; ARTICLE; CANCER STAGING; CARCINOGENESIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MELANOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; TISSUE MICROARRAY;

ADULT; AGED; CORE BINDING FACTOR ALPHA 3 SUBUNIT; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TISSUE ARRAY ANALYSIS; TRANSFORMING GROWTH FACTOR BETA;

EID: 79958800970     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25838     Document Type: Article

References (24)

1. Marks R., Epidemiology of melanoma. Clin Exp Dermatol. 2000; 25: 459-463.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ., Cancer statistics, 2009. CA Cancer J Clin. 2009; 59: 225-249.
3. Miller AJ, Mihm MC, Jr, Melanoma. N Engl J Med. 2006; 355: 51-65.
4. Jemal A, Thomas A, Murray T, Thun M., Cancer statistics, 2002. CA Cancer J Clin. 2002; 52: 23-47. (Pubitemid 34110469)
5. Lund AH, van Lohuizen M., RUNX: a trilogy of cancer genes. Cancer Cell. 2002; 1: 213-215. (Pubitemid 41039143)
6. Subramaniam MM, Chan JY, Yeoh KG, Quek T, Ito K, Salto-Tellez M., Molecular pathology of RUNX3 in human carcinogenesis. Biochim Biophys Acta. 2009; 1796: 315-331.
7. Javed A, Barnes GL, Pratap J, et al. Impaired intranuclear trafficking of Runx2 (AML3/CBFA1) transcription factors in breast cancer cells inhibits osteolysis in vivo. Proc Natl Acad Sci U S A. 2005; 102: 1454-1459. (Pubitemid 40209191)
8. Li QL, Ito K, Sakakura C, et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell. 2002; 109: 113-124. (Pubitemid 34327521)
9. Ito K, Lim AC, Salto-Tellez M, et al. RUNX3 attenuates beta-catenin/T cell factors in intestinal tumorigenesis. Cancer Cell. 2008; 14: 226-237.
10. Bae SC, Takahashi E, Zhang YW, et al. Cloning, mapping and expression of PEBP2 alpha C, a third gene encoding the mammalian Runt domain. Gene. 1995; 159: 245-248.
11. Hussein MR, Roggero E, Tuthill RJ, Wood GS, Sudilovsky O., Identification of novel deletion Loci at 1p36 and 9p22-21 in melanocytic dysplastic nevi and cutaneous malignant melanomas. Arch Dermatol. 2003; 139: 816-817. (Pubitemid 36705961)
12. Tsunematsu T, Kudo Y, Iizuka S, et al. RUNX3 has an oncogenic role in head and neck cancer. PLoS One. 2009; 4: e5892.
13. Kitago M, Martinez SR, Nakamura T, Sim MS, Hoon DS., Regulation of RUNX3 tumor suppressor gene expression in cutaneous melanoma. Clin Cancer Res. 2009; 15: 2988-2994.
14. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001; 19: 3622-3634. (Pubitemid 32786275)
15. Buzaid AC, Ross MI, Balch CM, et al. Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol. 1997; 15: 1039-1051. (Pubitemid 27106288)
16. Sakakura C, Miyagawa K, Fukuda KI, et al. Frequent silencing of RUNX3 in esophageal squamous cell carcinomas is associated with radioresistance and poor prognosis. Oncogene. 2007; 26: 5927-5938.
17. Wei D, Gong W, Oh SC, et al. Loss of RUNX3 expression significantly affects the clinical outcome of gastric cancer patients and its restoration causes drastic suppression of tumor growth and metastasis. Cancer Res. 2005; 65: 4809-4816. (Pubitemid 40740819)
18. Nagahama Y, Ishimaru M, Osaki M, et al. Apoptotic pathway induced by transduction of RUNX3 in the human gastric carcinoma cell line MKN-1. Cancer Sci. 2008; 99: 23-30. (Pubitemid 350239027)
19. Soengas MS, Lowe SW., Apoptosis and melanoma chemoresistance. Oncogene. 2003; 22: 3138-3151. (Pubitemid 36713766)
20. Pennison M, Pasche B., Targeting transforming growth factor-beta signaling. Curr Opin Oncol. 2007; 19: 579-585. (Pubitemid 47508864)
21. Ito Y, Miyazono K., RUNX transcription factors as key targets of TGF-beta superfamily signaling. Curr Opin Genet Dev. 2003; 13: 43-47. (Pubitemid 36143926)
22. Malaponte G, Zacchia A, Bevelacqua Y, et al. Co-regulated expression of matrix metalloproteinase-2 and transforming growth factor-beta in melanoma development and progression. Oncol Rep. 2010; 24: 81-87.
23. Weeraratna AT., A Wnt-er wonderland-the complexity of Wnt signaling in melanoma. Cancer Metastasis Rev. 2005; 24: 237-250. (Pubitemid 40922797)
24. Lin YC, You L, Xu Z, et al. Wnt inhibitory factor-1 gene transfer inhibits melanoma cell growth. Hum Gene Ther. 2007; 18: 379-386. (Pubitemid 46709349)